| Recruiting | GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL NCT06875063 | The First Affiliated Hospital of Xiamen University | Phase 1 |
| Recruiting | Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukem NCT06916767 | Paolo Caimi, MD | Phase 1 |
| Recruiting | Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma NCT06826118 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | Epco, Zanu, Ritux for R/R FL or MZL NCT06563596 | Reid Merryman, MD | Phase 2 |
| Recruiting | A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor NCT06615193 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) NCT06004167 | Massachusetts General Hospital | N/A |
| Unknown | Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study NCT05927558 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Unknown | Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia NCT05576532 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Withdrawn | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ an NCT06400264 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma NCT04870944 | Children's Oncology Group | Phase 1 / Phase 2 |
| Recruiting | Solving Riddles Through Sequencing NCT05046444 | Munich Leukemia Laboratory | — |
| Active Not Recruiting | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors NCT05071209 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Unknown | Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBC NCT04994626 | Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Avo In R/R And Previously Untreated MCL NCT04855695 | Austin I Kim | Phase 1 / Phase 2 |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and You NCT04500548 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Radiation Post-CAR T in Refractory Lymphoma NCT04473937 | Massachusetts General Hospital | N/A |
| Unknown | Dual Target CAR-T Cells in B-cell Lymphoma NCT04723914 | YuLi | Phase 1 / Phase 2 |
| Withdrawn | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumor NCT03925428 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Hae NCT04470947 | Medical University of Vienna | — |
| Completed | Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma NCT05006534 | National Taiwan University Hospital | — |
| Active Not Recruiting | Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol NCT06400251 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Sub NCT06400225 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H NCT06400238 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MAT NCT06308822 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) NCT05490771 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomo NCT03418038 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A NCT06385483 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or L NCT03323034 | Children's Oncology Group | Phase 1 |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification NCT06390839 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) NCT04439227 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATC NCT06390865 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z NCT06390852 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subp NCT06385496 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors NCT02780804 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol NCT06390826 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol NCT06357975 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MAT NCT06360575 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) NCT04439123 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol NCT04439344 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification ( NCT04439201 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) NCT04439240 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subproto NCT04439214 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N NCT04439149 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotoco NCT04439188 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subp NCT04439357 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-S NCT04439175 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1 NCT04439318 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) NCT04439305 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant NCT06357988 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) NCT06303167 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subp NCT04439331 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas NCT02323880 | Children's Oncology Group | Phase 1 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R NCT04439279 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATC NCT04439110 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) NCT04439266 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) NCT04439136 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATC NCT04439292 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G NCT04439253 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CN NCT02343718 | Canadian Cancer Trials Group | Phase 1 |
| Completed | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymp NCT01742988 | Curis, Inc. | Phase 1 |
| Completed | Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00054808 | Genta Incorporated | Phase 2 |